Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

IFS extends Boomi integration capabilities for IFS Cloud

Customer demand for integration platform as a service continues to growLondon, October 12, 2021 – Following the initial success of the partnership between global cloud enterprise applications company IFS  and leading cloud-based iPaaS provider Boomi , IFS is now unveiling enhanced connectivity to empower IFS Cloud customers to accelerate time to value.  The IFS-Boomi partnership, announced in February, 2020 

Vattenfall and AstaReal sign comprehensive energy contract Excess heat from algae cultivation will heat households in Gustavsberg

Vattenfall and AstaReal are expanding their cooperation through a comprehensive energy contract to recover excess heat from AstaReal’s algae cultivation. The idea is to be able to meet the heating requirements corresponding to 2,500 new apartments in Gustavsberg near Stockholm through the new partnership.“AstaReal’s production process is energy-intensive and requires both electricity and cooling. The excess heat that arises will be available for use for heating homes and premises. From spring 2022, Gustavsberg residents will have more than 20 percent of their heating requirements covered

Launch of Capitainer® B Vanadate, a blood sampling card that eliminates the risk of inaccurate test results when analyzing PEth.

Stockholm, Sweden, October 12, 2021. Swedish medtech scaleup Capitainer today announced the launch of its proprietary patent pending blood sampling card, Capitainer B Vanadate for accurate analysis of PEth, a key marker for long term alcohol use/abuse. Dried Blood Spot (DBS) sampling has been proposed as a method to solve the problem of post sampling formation of PEth occurring in traditional venous blood samples. However, the hematocrit effect gives negative impact on the accuracy due to uncertainty of the blood volume in DBS. Capitainer B Vanadate solves both problems in the same device

Launch of Capitainer® B Vanadate, a blood sampling card that eliminates the risk of inaccurate test results when analyzing PEth.

Stockholm, Sweden, October 12, 2021. Swedish medtech scaleup Capitainer today announced the launch of its proprietary patent pending blood sampling card, Capitainer B Vanadate for accurate analysis of PEth, a key marker for long term alcohol use/abuse. Dried Blood Spot (DBS) sampling has been proposed as a method to solve the problem of post sampling formation of PEth occurring in traditional venous blood samples. However, the hematocrit effect gives negative impact on the accuracy due to uncertainty of the blood volume in DBS. Capitainer B Vanadate solves both problems in the same

Bricknode expands Swedish presence with opening of new Stockholm office and new hires

Bricknode announced today the opening of its new office in Stockholm as the company expands its presence in Sweden. Adding to its Skövde headquarters, the new office will support key appointments including Martin de Bruin who joins the company as Head of Customer Success and Magnus Carlebjörk who joins as Product Manager.Commenting on the expansion and new appointments, Bricknode Founder & CEO Stefan Willebrand said, “Stockholm is one of Europe’s biggest fintech hubs and opening our new office there will allow us to work even more closely with customers and partners. It will also help us in

Free Background Checks in New Hampshire for Looking Up Public Records: The Best NH Criminal and Arrest Records Search Engines Online

You may find out all there is to know about your neighbors, friends, and even coworkers with a New Hampshire background check. Background checks can help you in lots of ways. Employers in New Hampshire use them to vet the ideal candidates and protect customers, vendors, and employees. These are additional great reasons to investigate someone's background after meeting him or her for the first time on a date or renting out a room to a new roommate. Running a background check for numerous causes can provide you with a wealth of information about someone. So if you want to know whether your

Rhino Tool House is revolutionizing manufacturing in the US with Ironhand 2.0

At Rhino Tool House, the core focuses are identifying and delivering the world’s most innovative industrial solutions to empower their customers to be more productive and maintain a safe environment for their workers. The Ironhand strengthening glove from Bioservo is one of the solutions they are offering customers, a solution that truly is revolutionizing both their customers productivity and work environment.[Ironhand 20 Production] Musculoskeletal disorders (MSDs) are the most common occupational diseases in industries in North America and the EU, as well as one of the main causes for

NRC Group ASA - Appointed to a contract in Sweden - SEK 43 million

The Swedish Transport Administration has appointed NRC Sverige AB, a company wholly owned by NRC Group ASA, to a contract for track related work in Örebro municipality. The contract is valued at approximately SEK 43 million, and will involve rail services such as track, electro, signal /telecom and groundwork. The work will commence in November 2021 and is scheduled for completion in November 2022. Closing date for submission of complaints is 10 days, and formal contractual signing can take place after this period at the earliest. For further information, please contact: Henning

Salipro Biotech enters into a collaboration and license agreement with AbCellera for access to the Salipro® Platform for antibody discovery against GPCRs, ion channels, and transporters

The collaboration enables AbCellera to access Salipro Biotech’s unique expertise and its Salipro® platform technology to generate stable antigens for challenging membrane protein drug targets for antibody discovery.Stockholm, Sweden, October 12, 2021 – Swedish biotech company Salipro Biotech AB today announced that it has entered into a collaboration and licensing agreement with AbCellera for access to its proprietary Salipro® Platform, which stabilizes challenging G protein coupled receptor (GPCR), ion channel, and transporter antigens. “We are excited to build on the success of our

The subscription period for Dicot’s rights issue begins today on October 12, 2021

Press release: Uppsala, October 12, 2021. Today on October 12, 2021, the subscription period for the rights issue in Dicot AB (publ) (”Dicot” or the ”Company”), which was made public on September 8, 2021 and resolved by the extra general meeting on October 6, 2021 (the ”Rights Issue”) commences.The subscription period for the Rights Issue will be from October 12, 2021 until October 27, 2021. Please note, however, that nominees may have a deadline for subscribing to the Rights Issue that occurs before October 27, 2021. Summary of the Rights Issue Subscription period: October 12,

Dignitana Honors Carla Thomas Cavalier as a DigniCap Dignitary

Diversity and Inclusion Strategist and Breast Cancer Survivor shares insights on inner strengthDignitana , world leader in scalp cooling innovation, has appointed Carla Thomas Cavalier of San Francisco, California, as its latest DigniCap Dignitary, the company’s patient advocacy and ambassador program. In this role, Ms. Cavalier will share insights from her personal experience with breast cancer to help others navigate their own journeys.   In recognition of Breast Cancer Awareness Month, Cavalier will be a featured guest in DigniCap’s new weekly Facebook Live

Invitation to presentation of Q3 interim report 2021

Nobia will publish its interim report for the third quarter 2021 on Tuesday October 26 at 08:30 CET.A webcasted telephone conference will be held the same day at 10.00 CET.Nobia’s President and CEO Jon Sintorn and CFO Kristoffer Ljungfelt will present the results and answer questions. The telephone conference will be webcasted live on Nobia’s website, or at https://edge.media-server.com/mmc/p/uemo9w89 Details for participation by telephone: Sweden:          +46 8 56 64 26 51UK:                 +44 33 33 00 08 04USA:               +1 631 913 1422Pin code:          6847 2664#

Invitation for presentation of Pricer’s interim report for the third quarter 2021

Pricer AB will present its interim report for the third quarter 2021 in an audiocast on October 22 at 13.00 CET.According to the financial calendar, Pricer will publish the report for the third quarter 2021 on Friday October 22 at approximately 8.30 CET. Pricer hereby invites to a presentation of the report on the same day. Pricer’s CEO Helena Holmgren will present the report and answer questions. Date: Friday October 22, 2021 Time: 13.00 CET Link to the audiocast: https://financialhearings.com/event/13243 For further information, please contact: Helena Holmgren, President

NENT Group names ‘Elvira’ as latest Danish Viaplay Original drama

· Offbeat drama series stars Sara Klein in debut leading role · ‘Elvira’ adapted from acclaimed novels by Anne-Sophie Lunding-Sørensen · NENT Group to premiere at least 60 Viaplay Originals in 2022 A first-time star portraying Denmark’s unlikeliest detective is the premise for ‘Elvira’, the next Danish Viaplay Original by Nordic Entertainment Group (NENT Group), one of the world’s fastest growing streaming companies. Starring rising talent Sara Klein and adapted from an acclaimed series of novels, the offbeat drama joins international hits such as ‘Face to Face’ and ‘Those Who Kill’

Navamedic ASA extends exclusive distribution rights for Mysimba in the Nordics

Oslo, 12 October 2021 – Navamedic ASA (OSE: NAVA) today announces it has exercised a five-year extension of its exclusive distribution rights for Mysimba® in the Nordics. Mysimba® is one of the fastest growing products in Navamedic’s portfolio, displaying sales growth of 89% in first half 2021 compared to the same period last year.Mysimba® is the first obesity treatment of its kind, combining both an oral medicin with a digital and custom-made patient support program to maximise patients’ success in treatment. Mysimba® reduces hunger and cravings, and provides control over food intake,

Invitation to presentation of Humana's report on third quarter 2021

Humana's interim report for the third quarter and nine-month period 2021 results will be published at 08:00 CET on November 11, 2021. A web-cast telephone conference will be held at 09:00 CET the same day.The webcast, where CEO and President Rasmus Nerman and CFO Noora Jayasekara will present the report, will be accessible at Humana's website www.humanagroup.com. The presentation material will be published on the website before the conference starts. The webcast, and later the recorded version of the webcast, will also be available at www.financialhearings.com.To participate in the

iLOQ brings innovation and sustainable thinking to the World Economic Forum event week

The World Economic Forum (WEF) Annual Meeting will take place from 17–21 January 2022 in Davos-Klosters, Switzerland, under the theme Working Together, Restoring Trust. The WEF’s mission is to bring together the most significant leaders from all sectors of global society to identify the best ways of addressing the world’s most pressing challenges. An important topic at next year’s event will be setting the agenda for shaping a more sustainable future. Digital locking and mobile access solutions company, iLOQ, is proud to be participating in the global event and contributing to the

Salipro Biotech enters into a collaboration and license agreement with AbCellera

Salipro Biotech enters into a collaboration and license agreement with AbCellera for access to the Salipro® Platform for antibody discovery against GPCRs, ion channels, and transporters The collaboration enables AbCellera to access Salipro Biotech’s unique expertise and its Salipro® platform technology to generate stable antigens for challenging membrane protein drug targets for antibody discovery.Stockholm, Sweden, October 12, 2021 – Swedish biotech company Salipro Biotech AB today announced that it has entered into a collaboration and licensing agreement with AbCellera for access to

BioStock: Spago Nanomedical’s CDO is in place

Recently, First North-listed, Spago Nanomedical announced the recruitment of Paul Hargreaves as Chief Development Officer to oversee the company’s clinical development, with a particular focus on the Tumorad project and the leading candidate drug SN201. BioStock contacted Hargreaves to hear about his background, the new role and his expectations on the task ahead.Read the interview with Spago Nanomedical's CDO Paul Hargreaves at biostock.se: https://www.biostock.se/en/2021/10/spago-nanomedicals-cdo-is-in-place/ This is a press release from BioStock - Connecting Innovation & Capital.

NOTICE TO ATTEND ANNUAL GENERAL MEETING IN BUILDDATA GROUP AB

The shareholders of BuildData Group AB, reg.no 559136-0317 (the “Company”) are hereby summoned to the annual general meeting on Thursday, 11 November 2021 to be held by postal voting only.   In view of the current situation and considering the risk for spreading the coronavirus, the Board of Directors have decided, that the meeting shall be held without physical presence by shareholders exercising their right to vote by postal voting, in accordance with Section 22 of the Act (2020:198) on temporary exceptions to facilitate the execution of general meetings in companies and other

WindowMaster announces strong growing pipeline and record order intake but increased inflation and delayed execution results in reduced EBITDA outlook for 2021

Tuesday, October 12, 2021 09:00 CET Company Announcement No. 19-2021 – Inside InformationVedbæk, October 12, 2021 Highlights from 2021-Q3 YTDWindowMaster continues its growth in opportunity pipeline – both in numbers but more important growth in value. The order intake also grew in Q3 YTD 2021 – with a 14% increase compared to the same period in 2020 (12% to 2019). The 12-month rolling order intake is at 218 MDKK – resulting in a record high order back log. Overall demand is intact and growing. · Net sales for 2021-Q3 YTD ended at 157m DKK representing a 15% increase compared

Finnfund and University of Helsinki to invest together into microfinancing in Africa and Asia

Finnfund, a Finnish development financier and impact investor, announce today a EUR 10 million debt facility commitment to the Advans Group , one of the leading international microfinance group serving over one million clients in nine countries: Cambodia, Cameroon, Ghana, Democratic Republic of Congo, Cote d’Ivoire, Pakistan, Nigeria, Tunisia, and Myanmar. University of Helsinki participates in this investment with Finnfund. Through this funding, Finnfund and University of Helsinki aim to generate funding for micro and small businesses and promote

Verifying results of efficacy for RCD405

Respiratorius reports positive preclinical milestone results from an ex vivo efficacy study of RCD405. The study has been conducted at a contract laboratory specialised in performing efficacy studies using human biospecimens, such as human lung tissue.In the study, RCD405 has been evaluated together with well-known bronchodilatory compounds in airway tissue from different species, i. e. rat, dog, and human. In all experiments a concentration-dependent dilatory effect of RCD405 was observed after induced constriction. In human airway tissue the relaxation was substantial and at least in the

BioStock Studio: Xintela expands to venous leg ulcers

Xintela has broadened the clinical development of its stem cell product XSTEM to include venous leg ulcers, the most common form of difficult-to-heal wounds in humans. Together with the Burn Centre at Linköping University Hospital, the company has shown that XSTEM provides good wound healing in a preclinical model. The next step for the company will be to apply for a clinical study in patients with venous leg ulcers, a study that Professor Folke Sjöberg from the Burn Centre tells us more about below.Watch the interview with Professor Folke Sjöberg at biostock.se: https://www.biostock.se/

There are no items matching the current filter
There are no more items matching the current filter
Back to top